Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebold, Nicholas, Morrisette, Taylor, Lagnf, Abdalhamid M, Alosaimy, Sara, Holger, Dana, Barber, Katie, Justo, Julie Ann, Antosz, Kayla, Carlson, Travis J, Frens, Jeremy J, Biagi, Mark, Kufel, Wesley D, Moore, William J, Mercuro, Nicholas, Raux, Brian R, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661073/
https://www.ncbi.nlm.nih.gov/pubmed/34901302
http://dx.doi.org/10.1093/ofid/ofab554
_version_ 1784613314104393728
author Rebold, Nicholas
Morrisette, Taylor
Lagnf, Abdalhamid M
Alosaimy, Sara
Holger, Dana
Barber, Katie
Justo, Julie Ann
Antosz, Kayla
Carlson, Travis J
Frens, Jeremy J
Biagi, Mark
Kufel, Wesley D
Moore, William J
Mercuro, Nicholas
Raux, Brian R
Rybak, Michael J
author_facet Rebold, Nicholas
Morrisette, Taylor
Lagnf, Abdalhamid M
Alosaimy, Sara
Holger, Dana
Barber, Katie
Justo, Julie Ann
Antosz, Kayla
Carlson, Travis J
Frens, Jeremy J
Biagi, Mark
Kufel, Wesley D
Moore, William J
Mercuro, Nicholas
Raux, Brian R
Rybak, Michael J
author_sort Rebold, Nicholas
collection PubMed
description A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
format Online
Article
Text
id pubmed-8661073
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86610732021-12-10 Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections Rebold, Nicholas Morrisette, Taylor Lagnf, Abdalhamid M Alosaimy, Sara Holger, Dana Barber, Katie Justo, Julie Ann Antosz, Kayla Carlson, Travis J Frens, Jeremy J Biagi, Mark Kufel, Wesley D Moore, William J Mercuro, Nicholas Raux, Brian R Rybak, Michael J Open Forum Infect Dis Brief Reports A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects. Oxford University Press 2021-12-09 /pmc/articles/PMC8661073/ /pubmed/34901302 http://dx.doi.org/10.1093/ofid/ofab554 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Rebold, Nicholas
Morrisette, Taylor
Lagnf, Abdalhamid M
Alosaimy, Sara
Holger, Dana
Barber, Katie
Justo, Julie Ann
Antosz, Kayla
Carlson, Travis J
Frens, Jeremy J
Biagi, Mark
Kufel, Wesley D
Moore, William J
Mercuro, Nicholas
Raux, Brian R
Rybak, Michael J
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title_full Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title_fullStr Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title_full_unstemmed Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title_short Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
title_sort early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661073/
https://www.ncbi.nlm.nih.gov/pubmed/34901302
http://dx.doi.org/10.1093/ofid/ofab554
work_keys_str_mv AT reboldnicholas earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT morrisettetaylor earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT lagnfabdalhamidm earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT alosaimysara earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT holgerdana earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT barberkatie earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT justojulieann earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT antoszkayla earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT carlsontravisj earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT frensjeremyj earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT biagimark earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT kufelwesleyd earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT moorewilliamj earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT mercuronicholas earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT rauxbrianr earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections
AT rybakmichaelj earlymulticenterexperiencewithimipenemcilastatinrelebactamformultidrugresistantgramnegativeinfections

Ejemplares similares